证券代码：300181 证券简称：佐力药业 公告编号：2025-069 1、案件所处的诉讼阶段：一审判决（驳回原告全部诉讼请求）。 二、本次诉讼的进展情况 2、上市公司控股子公司所处的当事人地位：被告。 3、涉案金额：111,375,804.89 元。 浙江佐力药业股份有限公司 4、对上市公司损益产生的影响：本次诉讼一审判决驳回原告全部诉讼请求， 公司控股子公司胜诉。如原告未在法定期限内上诉，本次诉讼将不会对公司本期 利润或期后利润产生负面影响。公司将持续关注案件后续进展，并及时履行信息 披露义务。 关于控股子公司涉诉的进展公告 一、本次诉讼的基本情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2023 年 12 月，浙江佐力药业股份有限公司（以下简称"佐力药业"或"公司"） 控股子公司青海珠峰冬虫夏草药业有限公司（以下简称"珠峰药业"）收到浙江省 高级人民法院（以下简称"浙江高院"）发来的《民事起诉状》《浙江省高级人民 法院一审案件受理/应诉通知书》等材料，原告杭州中美华东制药有限公司（以 下简称"华东制药"）与被告青海珠峰冬虫夏草原料有限公司（以下简 ...

Group 1 - The core viewpoint of the news highlights the significant increase in the success rate of national medical insurance negotiations, reaching a historical high, which is expected to encourage the development of innovative drugs in China [2] - The 2025 National Medical Insurance Drug List will add 114 new drugs, including 50 first-class innovative drugs, with an overall success rate of 88%, marking a notable increase from 76% in 2024 [1] - The new drug list will officially implement on January 1, 2026, expanding the total number of drugs covered to 3,253, enhancing coverage in key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1] Group 2 - Citic Securities believes that the successful negotiation rate for national medical insurance has reached a historical high, and the commercial insurance directory is expected to become an important growth driver, promoting the development of innovative drugs [2] - Guotai Junan Securities indicates that the recent press conference and series of discussions by the medical insurance bureau clarify future policies that support companies in "anti-involution," international expansion, and differentiated innovation, which will benefit the high-quality development of the medical device industry [2] - The China Innovation Drug ETF closely tracks the China Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2]

12月4日，国际医学公告称，公司拟定增募资不超10.08亿元。国际医学表示，公司本次募集资金将重点 投向智慧康养项目，该项目将使用公司旗下闲置场地开展，盘活存量资产。此外，国际医学还拟将部分 募集资金投入质子治疗中心二期项目，旨在打造、完善西北地区头一家投用的质子治疗项目，紧抓市场 机遇，带动中西部地区肿瘤治疗水平提升。 12月3日，佐力药业公告称，拟发行可转债募资不超15.56亿元。投向智能化中药大健康工厂(一期)、"乌 灵+X"产品研发项目以及补充流动资金。据悉，自2011年上市以来，公司累计已完成三次股权融资，募 资金额为18.66亿元。截至目前，公司累计分红金额达14.42亿元，分红率达57.96%。 12月以来，医药企业融资密集。值得注意的是，截至目前，已有至少5家医药上市公司启动再融资，涵 盖港股配售、A 股定增、可转债发行和资产证券化四大模式。 近日，三生制药公告称拟以每股29.62港元配售价配售1.051695亿股、占其发行后股份总数约4.14%，配 股融资总额约31.1512亿港元，融资净额30.8684亿港元。所得资金将用于全球及中国研发、基础设施建 设、设施购置及一般用途。摩根士丹利担任 ...

佐力药业（300181.SZ）核心产品销量稳健增长，计划募集资金扩产。 长江商报消息 ●长江商报记者 潘瑞冬 12月2日晚间，佐力药业发布公告称，公司拟向不特定对象发行可转换公司债券，募集资金总额不超过 15.56亿元，主要用于智能化中药大健康工厂（一期）建设、"乌灵+X"产品研发项目及补流，为公司核 心业务升级与创新发展提供资金支撑。 近年来，佐力药业受益于核心产品的需求增长，业绩稳增。上市以来，公司累计实现归母净利润24.87 亿元。2025年前三季度，公司的归母净利润为5.1亿元，超2024年全年。 首次可转债融资15.56亿 佐力药业计划首次通过可转债募资，用于扩产并补充流动性。 12月2日晚，佐力药业发布公告称，公司拟向不特定对象发行可转换公司债券，募集资金总额不超过 15.56亿元。募集资金将主要投向三大方向，其中10.9亿元用于智能化中药大健康工厂（一期）项目， 2.16亿元投入"乌灵+X"产品研发项目，2.5亿元用于补充流动资金。 公司表示，智能化工厂的建设将提升公司中药生产的自动化与智能化水平，"乌灵+X"研发项目则聚焦 核心产品延伸与创新，补充流动资金可优化公司财务结构，支持业务持续扩张。 ...

Core Viewpoint - Dongwu Securities report indicates that Zhaoli Pharmaceutical plans to issue convertible bonds to build capacity and develop "Wuling + X" products, supporting long-term growth [1] Group 1: Production and Capacity Expansion - The production scale of Wuling capsules and Bailing capsules is expected to continue growing in the near future [1] - The new production base and capacity expansion project are necessary measures to ensure market supply, consolidate industry position, and support strategic goals [1] Group 2: Research and Development Investment - Increased R&D investment will enrich the Wuling product series [1] - The main purpose of the fundraising project is for the development of innovative drugs and health products in the Wuling series [1] Group 3: Shareholder Returns - The company has maintained a dividend payout ratio around 80% since 2022, ranking among the top in the industry [1] - Considering the company's combination of high growth and high dividends, and the expected continuous release of core product performance in 2026, a "buy" rating is maintained [1]

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

中国经济网北京12月3日讯佐力药业（300181）(300181.SZ)昨晚披露的向不特定对象发行可转换公司债 券预案显示，公司本次向不特定对象发行可转换公司债券募集资金总额不超过155,612.03万元(含本 数)，扣除发行费用后的募集资金净额拟用于以下项目：智能化中药大健康工厂(一期)、"乌灵+X"产品 研发项目和补充流动资金。 本次发行证券的种类为可转换为公司股票的可转换公司债券。该可转债及未来转换的股票将在深圳证券 交易所创业板上市。 本次发行的可转债每张面值为人民币100元，按面值发行。本次发行的可转债的期限为自发行之日起6 年。 本次发行的可转债采用每年付息一次的付息方式，到期归还所有未转股的可转债本金并支付最后一年利 息。 本次发行的可转债转股期自可转债发行结束之日起满6个月后的第一个交易日起至可转债到期日止(如遇 法定节假日或休息日延至其后的第一个工作日；顺延期间付息款项不另计息)。可转债持有人对转股或 者不转股有选择权，并于转股的次日成为公司股东。 本次可转债的发行对象为持有中国证券登记结算有限责任公司深圳分公司证券账户的自然人、法人、证 券投资基金、符合法律规定的其他投资者等(国家法律、法 ...

Investment Rating - The report maintains a "Buy" rating for Zhaoli Pharmaceutical [1] Core Views - The company plans to issue convertible bonds to fund capacity expansion and R&D for "Wuling + X" products, supporting long-term growth [8] - The core products, Wuling series and Bailing series, have shown significant growth in both production and sales, with Wuling capsule production and sales expected to continue increasing [8] - The company emphasizes shareholder returns, committing to a cash distribution of at least 10% of distributable profits annually, with a minimum of 80% cash dividends during mature phases without major capital expenditures [8] - The financial forecasts indicate a steady increase in revenue and net profit, with projected net profits of 6.55 billion, 8.41 billion, and 10.41 billion for 2025-2027 [8] Financial Summary - Total revenue is projected to grow from 1,942 million in 2023 to 4,104 million by 2027, with a CAGR of approximately 16.20% [1] - Net profit attributable to shareholders is expected to rise from 382.94 million in 2023 to 1,041.23 million in 2027, reflecting a CAGR of about 23.87% [1] - The latest diluted EPS is forecasted to increase from 0.55 in 2023 to 1.48 in 2027, indicating strong earnings growth [1] - The current P/E ratio is projected to decrease from 31.60 in 2023 to 11.62 in 2027, suggesting an attractive valuation as earnings grow [1]

Group 1 - The core viewpoint of the news is that Zhaoli Pharmaceutical's stock has experienced fluctuations, with a recent decline in share price and a mixed performance in terms of trading volume and capital flow [1] - As of December 3, Zhaoli Pharmaceutical's stock price was 16.89 yuan per share, with a market capitalization of 11.846 billion yuan and a trading volume of 83.0143 million yuan [1] - The company has seen a year-to-date stock price increase of 14.37%, but has experienced declines of 1.05% over the last five trading days, 1.57% over the last twenty days, and 8.80% over the last sixty days [1] Group 2 - For the period from January to September 2025, Zhaoli Pharmaceutical reported a revenue of 2.28 billion yuan, representing a year-on-year growth of 11.48%, and a net profit attributable to shareholders of 510 million yuan, reflecting a growth of 21.00% [2] - The company has distributed a total of 1.442 billion yuan in dividends since its A-share listing, with 942 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased to 41,400, while the average circulating shares per person decreased by 6.82% to 14,562 shares [2][3]

这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动 向 全国医疗卫生机构总诊疗人次超101亿 12月2日，国家卫生健康委发布的《2024年我国卫生健康事业发展统计公报》显示，2024年，全国医疗 卫生机构总诊疗人次101.5亿，比上年增加6.0亿人次，居民人均预期寿命达到79.0岁，孕产妇死亡率下 降至14.3/10万，婴儿死亡率下降至4.0‰。根据公报，我国卫生资源总量持续稳步增长。2024年末，全 国医疗卫生机构总数1093551个，比上年增加22766个，其中医院38710个，比上年增加355个。2024年 末，卫生技术人员1302.0万人，比上年增加53.1万人(增长4.3%)，其中医院卫生技术人员937.4万人。 公报表明，我国次均医疗费用控制有成效。2024年，医院次均住院费用9870.0元，按当年价格比上年下 降4.3%，按可比价格下降4.5%；次均门诊费用361.0元，按当年价格比上年下降0.2%，按可比价格下降 0.4%。2024年全国卫生总费用初步核算为90895.5亿元。其中，政府卫生支出占24.9%，社会卫生支出占 47.6%，个人卫生支 ...